In a pilot trial highlighted by Ktori (2025), spinal cord stimulation showed promising results for adults with Spinal Muscular Atrophy (SMA). The study involved three adults and provided evidence that neurotechnology might be capable of reversing neural circuit degeneration and rescuing cell function in neurodegenerative diseases. This marks a potentially significant advancement in the treatment of SMA.
The findings suggest that through the use of spinal cord stimulation, patients experienced improvements in leg strength and walking ability. Although the sample size was small, the results of this trial could pave the way for larger studies and offer hope for new therapeutic strategies in SMA and similar conditions. The research indicates a new horizon in the management of SMA, emphasizing the potential of neurotechnology to improve the quality of life for those affected by such diseases.
